# Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

> **NCT05660954** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 41 (actual)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT05660954
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-25
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05660954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05660954, "Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05660954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*